Business Context and Reporting Period
Company: Harmony Biosciences Holdings, Inc. (HRMY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Harmony is a commercial-stage neuroscience company focused on rare neurological diseases. Its primary revenue driver is WAKIX (pitolisant), a first-in-class, non-scheduled treatment for narcolepsy (excessive daytime sleepiness and cataplexy) in adults and pediatric patients. The company is expanding its portfolio through acquisitions (Epygenix, Zynerba) and strategic licensing (Bioprojet, CiRC) to address rare epilepsy, neurobehavioral disorders, and new indications for pitolisant.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Net Product Revenue | $868.5 million | $714.7 million |
| Gross Profit | $670.1 million | $557.9 million |
| Gross Margin | 77.2% | 78.1% |
| Operating Income | $208.5 million | $190.8 million |
| Net Income | $158.7 million | $145.5 million |
| Diluted EPS | $2.71 | $2.51 |
| Operating Cash Flow | $348.2 million | $219.8 million |
| Cash, Cash Equivalents & Investments | $882.5 million | $467.2 million |
| Total Debt (Outstanding) | $165.0 million | $181.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 21.5% to $868.5 million, driven by an 18.3% increase in units shipped and a 7.0% price increase implemented in January 2025, partially offset by higher rebates.
- Cost of Sales: Increased 26.5% to $198.3 million. The gross margin percentage decreased slightly (77.2% vs 78.1%) primarily due to triggering a higher royalty tier under the 2017 Bioprojet License Agreement earlier in 2025.
- Operating Expenses:
- R&D: Increased 30.0% to $189.6 million, driven by clinical progression of EPX-100, ZYN002, and Pitolisant GR/HD, offset by lower IPR&D charges compared to 2024.
- Sales & Marketing: Increased 7.8% to $119.5 million due to expanded patient engagement and higher headcount.
- G&A: Increased 38.2% to $152.5 million, largely due to a $39.0 million increase in legal and professional fees associated with patent litigation settlements.
- Acquisitions & Milestones: Significant IPR&D charges in 2024 related to the Epygenix acquisition ($17.1M) and Bioprojet Sublicense ($25.5M) were lower in 2025, though 2025 included milestone payments for ZYN002 ($15.0M) and BP1.15205 ($4.3M).
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Commercial Performance: Average number of patients on WAKIX in Q4 2025 was approximately 8,500. Formulary access secured for over 80% of insured lives in the U.S.
- Pipeline Progress:
- WAKIX: FDA approved for pediatric cataplexy in February 2026. Phase 3 TEMPO study for Prader-Willi Syndrome (PWS) initiated in Q1 2024.
- Pitolisant GR: Positive bioequivalence data announced in Q4 2025; NDA submission expected early 2026 with a target PDUFA date in Q1 2027.
- Pitolisant HD: Phase 3 registrational trials (ONSTRIDE1/2) initiated in Q4 2025; topline data expected in 2027.
- EPX-100: Phase 3 trials for Dravet Syndrome and Lennox-Gastaut Syndrome ongoing; positive open-label extension data announced in December 2025.
- ZYN002: Phase 3 RECONNECT study for Fragile X Syndrome did not meet primary endpoint; program being phased out.
- Liquidity: Management believes existing cash and investments ($882.5M) are sufficient to fund operations for at least the next 12 months.
Risks and Contingencies
- Product Dependence: Substantially dependent on WAKIX for revenue; failure to maintain sales would materially harm financial condition.
- Patent Litigation: Settled multiple ANDA (generic) lawsuits with Lupin, Novugen, Novitium, Hikma, Annora, and MSN in 2025/2026. Settlements generally allow generic entry in July 2030 (or March 2030 for Hikma) if pediatric exclusivity is granted.
- Regulatory & Pricing: Risks related to the Inflation Reduction Act (IRA) and potential new federal pricing policies (e.g., "Globe and Guard" regulations) could impact reimbursement and net prices.
- Development Risks: Clinical trials for new indications (PWS, DM1, IH) and new assets (EPX-100, BP1.15205) carry inherent risks of failure or delay.
Key Facts for Investor Verification
- Revenue Concentration: Verify the continued growth trajectory of WAKIX and the impact of the 2025 price increase on net revenue after rebates.
- Patent Expiry & Generic Entry: Confirm the specific launch dates for generic pitolisant based on the settlement agreements (targeting 2030) and the status of pediatric exclusivity which could extend protection.
- Pipeline Milestones: Monitor the submission and approval timeline for Pitolisant GR (NDA expected early 2026) and the topline data for Pitolisant HD and EPX-100 (expected 2027).
- Debt Covenants: Review compliance with the Term Loan A Credit Agreement covenants, particularly regarding leverage ratios and liquidity.
- Acquisition Integration: Assess the commercial viability of the Epygenix assets (EPX-100) following the positive Phase 3 extension data.